Ctrl

K

Streptozocin

Class
DNA crosslinking agents
Subclass
Alkylating agents
Generic name
Streptozocin
Brand names
Zanosar®
Indications for use
Labeled indications
Adults
•
Treatment of islet cell pancreatic cancer (metastatic)
Off-label indications
Adults
•
Treatment of carcinoid syndrome
•
Treatment of colon cancer
Safety risks
Warnings and precautions
Chemotherapy-induced bone marrow suppression
•
Use caution with a history of neutropenia and/or thrombocytopenia.
Hypoglycemia
•
Use caution with diabetes mellitus.
Hypophosphatemia, proteinuria, nephrotoxicity
•
Use caution with renal impairment.
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
•
Use acceptable. No dose adjustment required.
Renal replacement therapy
Any modality
•
Use acceptable. No dose adjustment required.
Hepatic impairment
Any severity
•
Use with caution. Monitor serum aminotransferases. Monitor for toxicity.
Pregnancy and breastfeeding
Pregnancy
All trimesters
•
Avoid use. Evidence of fetal harm in humans.
Breastfeeding
Do not use during breastfeeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
•
Nausea, vomiting
Common 1-10%
•
Anemia, ↓ WBC count, ↓ platelet count
Unknown frequency
•
AKI, abnormal oral glucose tolerance test, ↓ blood glucose, ↓ serum phosphate, drug-induced liver injury, edema, hypoalbuminemia, ↑ BUN, ↑ body temperature, ↑ liver enzymes, ↑ urine glucose, ↑ urine protein, lethargy, nephrogenic diabetes insipidus, renal tubular necrosis, confusion, depression, injection site reactions, low urine output, skin injury, tissue necrosis
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource